EMERGENCY USE AUTHORIZATION (EUA) SUMMARY
SARS-CoV-2 MOLECULAR DETECTION ASSAY
(MAYO CLINIC)

For In vitro Diagnostic Use
Rx Only
For use under Emergency Use Authorization (EUA) only

(The SARS-CoV-2 Molecular Detection Assay will be performed at the Mayo Clinic, located at 200 1st St. NW, Rochester, MN 55905, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a and meets the requirements to perform high complexity tests as per the Laboratory Instructions for Use that was reviewed by the FDA under this EUA.)

INTENDED USE

The SARS-CoV-2 Molecular Detection Assay is a real-time PCR test using TaqMan chemistry and is intended for the qualitative detection of nucleic acid from SARS-CoV-2 in upper and lower respiratory specimens (such as nasopharyngeal swabs, throat swabs, nasal swabs, sputum, tracheal secretions, BAL fluid, and bronchial washings) from individuals suspected of COVID-19 by their healthcare provider. Testing is limited to Mayo Clinic Laboratories, Rochester, MN, certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a that meets requirements to perform high complexity tests.

Results are for the identification of SARS-CoV-2 RNA. SARS-CoV-2 RNA is generally detectable in upper and lower respiratory specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities.

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.

Testing with the SARS-CoV-2 Molecular Detection Assay is intended for use by qualified and trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures. The SARS-CoV-2 Molecular Detection Assay is only for use under the Food and Drug Administration’s Emergency Use Authorization.
DEVICE DESCRIPTION AND TEST PRINCIPLE

The SARS-CoV-2 Molecular Detection Assay is a real-time reverse transcription polymerase chain reaction (rRT-PCR) test using the Roche LightCycler 480 II amplification system. The SARS-CoV-2 primer and probe set is designed to detect RNA from the SARS-CoV-2 nucleocapsid gene in a clinical sample. The nucleocapsid target was determined to be specific to SARS-CoV-2.

RNA is isolated/purified from upper respiratory specimens using the bioMérieux easyMAG and EMAG, Hamilton Microlab STAR utilizing Promega Maxwell HT Viral TNA kit, and Roche MagNa Pure 96 using MagNa Pure DNA and Viral NA Small Volume Kit and lower respiratory specimens using the bioMérieux easyMAG and EMAG. Extracted RNA is reverse transcribed to cDNA and subsequently amplified using the Roche LightCycler 480 II. During the amplification process, the probes anneal to specific target sequences located between the forward and reverse primers. During the extension phase of the PCR cycle, the 5’ nuclease activity of Taq polymerase degrades the probe, causing the reporter dye (FAM) to separate from the quencher dye, generating a fluorescent signal. With each cycle, additional reporter dye molecules are cleaved from their respective probes, increasing the fluorescence intensity. The dye labeled probe allows for detection of SARS-CoV-2 virus in the corresponding detector channel (465-510nm) of the LightCycler 480 II instrument.

INSTRUMENTS USED WITH TEST

The SARS-CoV-2 Molecular Detection Assay is to be used with the bioMérieux easyMAG and EMAG, Hamilton Microlab STAR, and Roche MagNa Pure 96 extraction instruments and Roche LightCycler 480 II version 1.5.1.62.

REAGENTS AND MATERIALS

<table>
<thead>
<tr>
<th>Reagent</th>
<th>Manufacturer</th>
<th>Catalog #</th>
</tr>
</thead>
<tbody>
<tr>
<td>SuperScript III Platinum One-step qRT-PCR Kit</td>
<td>Invitrogen</td>
<td>11732-088</td>
</tr>
<tr>
<td>SARS-CoV-2 NUC Primers</td>
<td>TIB MOBIOL, LLC</td>
<td>NUCF, NUCR</td>
</tr>
<tr>
<td>NUC TaqMan Probe</td>
<td>TIB MOBIOL, LLC</td>
<td>NUC-P530iQ2</td>
</tr>
<tr>
<td>Internal Control Primers</td>
<td>TIB MOBIOL, LLC</td>
<td>MHV-F, MHV-R</td>
</tr>
<tr>
<td>Internal Control TaqMan Probe</td>
<td>TIB MOBIOL, LLC</td>
<td>MHV-P</td>
</tr>
</tbody>
</table>
CONTROLS TO BE USED WITH THE SARS-CoV-2 MOLECULAR DETECTION ASSAY

1) **Negative Extraction (EXT)/Amplification (AMP) Control:** It is PCR-grade, nuclease free water which serves as the negative control (reagent contamination and extraction control). It is processed and tested on each assay run to ensure that no contamination has taken place in either the extraction or amplification phases of testing. This control contains all of the reagents for amplification but does not contain the targeted nucleic acid template.

2) **Positive Extraction (EXT)/Amplification (AMP) Control:** The extraction/amplification control contains synthetic DNA for the NUC target sequence and is used on every extraction run to ensure that adequate nucleic acid isolation has taken place. This control is processed through the extraction protocol followed by amplification and detection to ensure the reagents are functioning as expected, and that the run conditions and master mix were adequate for amplification to occur.

3) **Internal Control (IC):** IC contains a 1,000 copies/µL of an “artificial” RNA molecule with no homology to any other pathogens. It is added to the SARS-CoV-2 master mix and is reverse-transcribed, amplified and detected in each reaction. The MHV internal control ensures the integrity of the RT-PCR results by assessing for potential RT-PCR inhibition.

INTERPRETATION OF RESULTS

All test controls should be examined prior to interpretation of patient results. If the controls are not valid, the patient results cannot be interpreted.

1) **SARS-CoV-2 Molecular Detection Assay Controls – Positive, Negative and Internal**

   The negative template control must be negative (i.e., Undetected). The positive extraction/amplification control must be positive (i.e., Detected) with a crossing point (Cp) value within ± 3 cycles of the average Cp value established prior to the control being placed into use. The internal control must be positive in all negative samples, including the negative template control, to ensure no inhibition has occurred.
2) **Examination and Interpretation of Patient Specimen Results:**

The NUC target uses a FAM-labelled probe and the internal control is Cy5-labelled. Assessment of clinical specimen test results should be performed after the positive, negative and internal controls have been examined and determined to be valid and acceptable. If the positive and negative controls are not valid, the patient results cannot be interpreted/reported.

a. **Negative extraction/amplification control:**
   i. If the negative control is positive, all specimens must be re-extracted.

b. **Positive extraction/amplification control:**
   i. If the positive control is negative, all specimens must be re-extracted.
   
   **NOTE:** If the internal control for the positive control is invalid, but the negative control and majority of patient specimens yield valid internal control results, it is possible an adequate volume of master mix was not added to the positive control well. In this case, the amplification plate may be re-pipetted prior to re-extraction. If the positive control is valid after re-amplification, re-extraction is not necessary.

c. **Internal control (IC) failure:**
   i. If no IC amplification curve is present in the negative control:
      • Repeat entire run (extraction and amplification) including controls.
      • If negative control repeats with a valid IC amplification curve, results can be reported.
      • If the negative control repeats with no IC amplification curve, hold results and notify management staff for further review and direction.
   ii. If no internal control amplification curve is present in negative patient sample:
      • Repeat sample once (extraction and amplification).

Positive (i.e., Detected) patient sample results are those that have a Cp value ≤ 45 and a valid amplification curve, which is defined as having a clear upward inflection rising above the baseline. Negative (i.e., Undetected) results will not have a Cp value and will not yield an amplification curve. Indeterminate results are those that will show no Cp value but yield a smooth upward inflection rising above the baseline.

<table>
<thead>
<tr>
<th>NUC</th>
<th>NUC IC</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>+</td>
<td>+/-</td>
<td>Detected</td>
</tr>
<tr>
<td>-</td>
<td>+</td>
<td>Undetected</td>
</tr>
<tr>
<td>IND</td>
<td>+</td>
<td>Indeterminate</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>Inconclusive</td>
</tr>
</tbody>
</table>

NUC: Nucleocapsid

**LIMITATIONS**

- The use of SARS-CoV-2 Molecular Detection Assay as an *in vitro* diagnostic under the FDA Emergency Use Authorization (EUA) is limited to Mayo Clinic, located at
200 1st St. NW, Rochester, MN 55905 which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, and meets requirements to perform high complexity tests.

- The SARS-CoV-2 Molecular Detection Assay performance was established using specimen types listed. Other specimen types have not been evaluated and should not be tested with this assay.
- The detection of viral nucleic acid is dependent upon proper specimen collection, handling, transportation, storage, and preparation (including extraction). Failure to observe proper procedure in any one of these steps can lead to incorrect results.
- Extraction and amplification of nucleic acid from clinical samples must be performed according the specified methods listed in this procedure. Other extraction approaches and processing systems have not been evaluated.
- A false negative result may occur if a specimen is improperly collected, transported or handled. False negative results may also occur if amplification inhibitors are present in the specimen or if inadequate numbers of organisms are present in the specimen.
- False negative results can arise from:
  - Specimen collection conducted prior to symptom onset.
  - Failure to follow the authorized assay procedures.
  - Failure to use authorized extraction kit and platform.
- There is a risk of false negative values due to the presence of sequence variants in the viral targets of the assay.
- A false positive result may arise from cross contamination during specimen handling or preparation, or between patient samples.
- The impacts of vaccines, antiviral therapeutics, antibiotics, chemotherapeutic or immunosuppressant drugs have not been evaluated. The SARS-CoV-2 Molecular Detection Assay cannot rule out diseases caused by other bacterial or viral pathogens.
- Negative results do not preclude infection with SARS-CoV-2 virus and should not be the sole basis of a patient management decision.
- A trained health professional should interpret assay results in conjunction with the patient’s medical condition, clinical signs and symptoms, and the results of other diagnostic tests.

**WARNINGS**

- This test is for prescription use only;
- This test is for *in vitro* diagnostic use only;
- This test has not been FDA cleared or approved;
- This test has been authorized by FDA under an EUA for use by Mayo Clinic, located at 200 1st St. NW, Rochester, MN 55905;
- This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and
- This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection
and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

PERFORMANCE EVALUATION

1) Analytical Sensitivity/Limit of Detection (LoD):

The LoD study established the lowest concentration of SARS-CoV-2 (genome copies/µL) that can be detected by the SARS-CoV-2 Molecular detection Assay at least 95% of the time. The LoD of the SARS-CoV-2 Molecular Detection Assay was determined using a quantified SARS-CoV-2 positive clinical specimen. A preliminary LoD was determined by testing 2-fold serial dilutions of quantified SARS-CoV-2 clinical sample spiked into pooled SARS-CoV-2 negative nasopharyngeal (NP) and sputum samples, tested in replicates of 20. The LoD was confirmed by testing 20 replicates. The samples were prepared by spiking the quantified SARS-CoV-2 positive clinical specimen into negative respiratory clinical matrices (NP swabs and sputum). The samples were extracted by bioMérieux easyMAG and tested by the SARS-CoV-2 Molecular Detection Assay per the protocol. The study results showed that the LoD of the SARS-CoV-2 Molecular detection Assay is 0.156 copies/µL in NP swabs and 12.5 copies/µL in sputum samples. Additionally, a comparative study demonstrated that the LoDs obtained with two bioMérieux extractions (easyMAG and EMAG) are comparable.

Table 3: SARS-CoV-2 Molecular Detection Assay Confirmatory LoD Results in Upper and Lower Respiratory Samples

<table>
<thead>
<tr>
<th>Test</th>
<th>Source</th>
<th>Concentration (copies/mL)</th>
<th>No. tested</th>
<th>No. (% Positive)</th>
<th>Average Cp</th>
<th>Standard Deviation Cp</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NP Swabs</td>
<td>12,500</td>
<td>20</td>
<td>20 (100)</td>
<td>27.2</td>
<td>0.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6,250</td>
<td>20</td>
<td>17 (85)</td>
<td>27.6</td>
<td>0.4</td>
</tr>
<tr>
<td></td>
<td>156</td>
<td></td>
<td>20</td>
<td>20 (100)</td>
<td>30.7</td>
<td>0.9</td>
</tr>
<tr>
<td></td>
<td></td>
<td>78</td>
<td>20</td>
<td>16 (80)</td>
<td>31.0</td>
<td>0.8</td>
</tr>
</tbody>
</table>

NUC, nucleocapsid; Cp, crossing point

Extraction Systems Comparison:

20 NP swab samples spiked at 1x LoD were extracted with Hamilton Microlab STAR utilizing Promega Maxwell HT Viral TNA kit and Roche MagNa Pure 96 using MagNa Pure DNA and Viral NA Small Volume Kit in parallel with bioMérieux easyMAG. The extracted RNA from each extraction system was subsequently reverse transcribed and amplified using Roche LightCycler 480. The study results presented in Table 4 demonstrated that the two additional extraction systems, i.e., Hamilton Microlab STAR and Roche MagNa Pure 96 generated comparable results to bioMérieux easyMAG. For
both new extraction systems, the Cp values did not differ by more than 2 cycles with those obtained by the easyMAG system.

### Table 4: Results of Extraction System Comparison

<table>
<thead>
<tr>
<th>Concentration</th>
<th>Cp Values</th>
<th>easyMAG NUC</th>
<th>Hamilton STAR NUC</th>
<th>MagNa Pure 96 NUC</th>
</tr>
</thead>
<tbody>
<tr>
<td>1X LoD (156 copies/ml)</td>
<td>Average</td>
<td>31.27</td>
<td>30.50</td>
<td>31.93</td>
</tr>
<tr>
<td></td>
<td>SD</td>
<td>0.38</td>
<td>0.35</td>
<td>0.85</td>
</tr>
<tr>
<td></td>
<td>Total Positive</td>
<td>20</td>
<td>20</td>
<td>20</td>
</tr>
</tbody>
</table>

#### 2) Inclusivity:

Inclusivity was tested by performing an *in silico* analysis using all publicly available sequences of SARS-CoV-2 (taxid 2697049) from the National Center for Biotechnology Information (NCBI) located in GenBank as of April 9th, 2020. The analysis showed 99.6% homology when compared to nucleocapsid forward primer sequence, 99.2% homology when compared to nucleocapsid reverse primer sequence, and 92.1% homology when compared to nucleocapsid probe sequence with all available SARS-CoV-2 sequences. The mismatches in nucleocapsid primers and probe sequences showed single base pair mismatch; the majority of which occurred at the extreme terminus of the primers that should have minimal impact on the detection of the strains harboring this mismatch.

#### 3) Analytical Specificity:

Cross-reactivity of the SARS-CoV-2 Molecular Detection Assay was evaluated using both *in silico* analysis and by testing a cross-reactivity panel consisting of microorganisms that may be present in respiratory samples. High priority pathogens from the same genetic family as SARS-CoV-2, as well as organisms likely to be circulating in the population and found in the relevant clinical matrices were evaluated *in silico*.

### Table 5: Organisms Tested in the Cross-reactivity Testing of the SARS-CoV-2 Molecular Detection Assay

<table>
<thead>
<tr>
<th>Pathogen</th>
<th>Strain</th>
<th>GenBank Acc#</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV</td>
<td>Urbani isolate icSARS-C7-MA</td>
<td>MK062184.1</td>
</tr>
<tr>
<td>MERS-CoV</td>
<td>NL13845</td>
<td>MG021451.1</td>
</tr>
<tr>
<td>HCoV-229E</td>
<td>HCoV_229E/Seattle/USA/SC9724/2018</td>
<td>MN369046.1</td>
</tr>
<tr>
<td>229E-related bat CoV</td>
<td>BtKY229E-8</td>
<td>KY073748.1</td>
</tr>
<tr>
<td>HCoV-OC43</td>
<td>HCoV-OC43/USA/ACRI_0052/2016</td>
<td>MF314143.1</td>
</tr>
<tr>
<td>HCoV-HKU1</td>
<td>SI17244</td>
<td>MH940245.1</td>
</tr>
<tr>
<td>Pathogen</td>
<td>Strain</td>
<td>GenBank Acc#</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>---------------------------------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>HCoV-NL63</td>
<td>HCoV_NL63/Seattle/USA/SC0768/2019</td>
<td>MN306040.1</td>
</tr>
<tr>
<td><em>Legionella clemsonensis</em></td>
<td>CDC-D5610</td>
<td>CP016397.1</td>
</tr>
<tr>
<td>Human adenovirus C1</td>
<td>SH2016</td>
<td>MH183293.1</td>
</tr>
<tr>
<td>Human metapneumovirus 1</td>
<td>bj0123</td>
<td>MK820375.1</td>
</tr>
<tr>
<td>Human parainfluenza virus 2</td>
<td>HPIV2/Seattle/USA/SC9949/2018</td>
<td>MN369034.1</td>
</tr>
<tr>
<td>Human parainfluenza virus 3</td>
<td>HPIV3/USA/629-D00687/2008</td>
<td>KF530242.1</td>
</tr>
<tr>
<td>Human parainfluenza virus 4b</td>
<td>HPIV4b/Seattle/USA/SC0496/2019</td>
<td>MN306032.1</td>
</tr>
<tr>
<td>Influenza A</td>
<td>(A/chicken/Taiwan/1843/2012(H6N1))</td>
<td>KJ162810.1</td>
</tr>
<tr>
<td>Influenza B</td>
<td>(B/Guangzhou/01/2007)</td>
<td>EU305612.1</td>
</tr>
<tr>
<td>Enterovirus D68</td>
<td>USA/CA/1962-23234</td>
<td>MN240508.1</td>
</tr>
<tr>
<td>Human respiratory syncytial</td>
<td>MaxFLC</td>
<td>MK733769.1</td>
</tr>
<tr>
<td>Rhinovirus C</td>
<td>3430-MY-10</td>
<td>KJ675507.1</td>
</tr>
<tr>
<td>Influenza C</td>
<td>(C/Iwate/2/2016)</td>
<td>LC327663.1</td>
</tr>
<tr>
<td>Parechovirus A</td>
<td>CDMS</td>
<td>MK904604.1</td>
</tr>
<tr>
<td><em>Chlamydophila pneumoniae</em></td>
<td>LPCoLN</td>
<td>CP001713.1</td>
</tr>
<tr>
<td><em>Haemophilus influenzae</em></td>
<td>NCTC8468</td>
<td>LR590465.1</td>
</tr>
<tr>
<td><em>Legionella pneumophila</em></td>
<td>ERS1305867</td>
<td>CP048618.1</td>
</tr>
<tr>
<td><em>Mycobacterium tuberculosis</em></td>
<td>TCDC11</td>
<td>CP046728.2</td>
</tr>
<tr>
<td><em>Streptococcus pneumoniae</em></td>
<td>M26365</td>
<td>CP031248.1</td>
</tr>
<tr>
<td><em>Streptococcus pyogenes</em></td>
<td>MGAS6180</td>
<td>CP000056.2</td>
</tr>
<tr>
<td><em>Bordetella pertussis</em></td>
<td>J348</td>
<td>CP033416.1</td>
</tr>
<tr>
<td><em>Mycoplasma pneumoniae</em></td>
<td>16-734</td>
<td>CP039761.1</td>
</tr>
<tr>
<td>Pneumocystis jirovecii (PJP)</td>
<td>RU7</td>
<td>GCF_001477535.1</td>
</tr>
<tr>
<td><em>Candida albicans</em></td>
<td>SC5314-P0</td>
<td>GCA_00283767.5</td>
</tr>
<tr>
<td><em>Corynebacterium diphtheriae</em></td>
<td>BQ11</td>
<td>CP029644.1</td>
</tr>
<tr>
<td><em>Neisseria elongata</em></td>
<td>M15910</td>
<td>CP031255.1</td>
</tr>
<tr>
<td><em>Neisseria meningitidis</em></td>
<td>M18727</td>
<td>CP031333.1</td>
</tr>
<tr>
<td><em>Staphylococcus epidermidis</em></td>
<td>NCCP 16828</td>
<td>CP043847.1</td>
</tr>
<tr>
<td>Leptospirosis</td>
<td>FCAS KW2</td>
<td>CP039256.1</td>
</tr>
<tr>
<td><em>Staphylococcus aureus</em></td>
<td>79_S10</td>
<td>CP010944.1</td>
</tr>
<tr>
<td><em>Bacillus anthracis</em> (Anthrax)</td>
<td>BF1</td>
<td>CP047131.1</td>
</tr>
<tr>
<td><em>Moraxella catarrhalis</em></td>
<td>MC8</td>
<td>CP010902.1</td>
</tr>
<tr>
<td><em>Pseudomonas aeruginosa</em></td>
<td>VIT PC9</td>
<td>CP048791.1</td>
</tr>
<tr>
<td><em>Streptococcus salivarius</em></td>
<td>ICDC2</td>
<td>CP018187.1</td>
</tr>
<tr>
<td><em>Chlamydia psittaci</em></td>
<td>AMK</td>
<td>CP047319.1</td>
</tr>
<tr>
<td><em>Coxiella burnetii</em> (Q-Fever)</td>
<td>RSA439</td>
<td>CP040059.1</td>
</tr>
</tbody>
</table>
When the *in silico* analysis showed ≥80% homology of any SARS-CoV-2 primer or probe with another pathogen, a single replicate of the organism was tested using the SARS-CoV-2 Molecular Detection Assay to assess cross-reactivity. These results are summarized in table below:

### Table 6: Cross-reactivity panel tested by the SARS-CoV-2 Molecular Detection Assay

<table>
<thead>
<tr>
<th>Organism</th>
<th>Source</th>
<th>NUC PCR Assay</th>
<th>Genomes/µL</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV N gene(^1)</td>
<td>IDT 10006624</td>
<td>Negative</td>
<td>2.00E+05</td>
</tr>
<tr>
<td>SARS-CoV ORF1ab gene</td>
<td>IDT Ref #264728633</td>
<td>Negative</td>
<td>2.00E+05</td>
</tr>
<tr>
<td>MERS-CoV</td>
<td>ATCC VR-3248SD</td>
<td>Negative</td>
<td>1.00E+06</td>
</tr>
<tr>
<td>HCoV-OC43</td>
<td>ATCC VR-3263SD</td>
<td>Negative</td>
<td>1.00E+06</td>
</tr>
<tr>
<td>HCoV-HKU1</td>
<td>ATCC VR-3262SD</td>
<td>Negative</td>
<td>1.00E+06</td>
</tr>
<tr>
<td>HCoV-NL63</td>
<td>ATCC VR-1558SD</td>
<td>Negative</td>
<td>1.00E+06</td>
</tr>
<tr>
<td><em>Hemophilus influenzae</em></td>
<td>ATCC 10211</td>
<td>Negative</td>
<td>4.36E+09</td>
</tr>
<tr>
<td><em>Streptococcus pneumonia</em></td>
<td>ATCC 49619</td>
<td>Negative</td>
<td>1.60E+10</td>
</tr>
<tr>
<td><em>Streptococcus pyogenes</em></td>
<td>ATCC 19615</td>
<td>Negative</td>
<td>2.96E+09</td>
</tr>
<tr>
<td><em>Candida albicans</em></td>
<td>ATCC 60193</td>
<td>Negative</td>
<td>5.70E+08</td>
</tr>
<tr>
<td><em>Staphylococcus aureus</em></td>
<td>ATCC 25923</td>
<td>Negative</td>
<td>4.24E+09</td>
</tr>
<tr>
<td><em>Bacillus anthracis</em> (Anthrax)</td>
<td>LRN Survey Strain</td>
<td>Negative</td>
<td>2.15E+08</td>
</tr>
<tr>
<td><em>Moraxella catarrhalis</em></td>
<td>ATCC 8176</td>
<td>Negative</td>
<td>1.66E+09</td>
</tr>
<tr>
<td><em>Pseudomonas aeruginosa</em></td>
<td>ATCC 27853</td>
<td>Negative</td>
<td>1.55E+10</td>
</tr>
</tbody>
</table>

\(^1\)This control from IDT consists of the N gene from SARS-CoV (2003). This is NOT detected by the SARS-CoV-2 MDA assay, as the N target is specific for SARS-CoV-2.

### 4) Clinical Evaluation:

A contrived clinical study was performed to evaluate the performance of the SARS-CoV-2 Molecular Detection Assay. 20 analyte-negative NP swabs and 20 analyte-negative sputum samples were spiked with a quantified, positive clinical sample at 1x LoD (i.e., 0.156 copies/µL for NP swabs; 12.5 copies/µL for sputum) and 2x LoD (i.e., 0.312 copies/µL for NP swabs; 25 copies/µL for sputum). In addition, 10 analyte-negative throat swabs and 10 analyte-negative BAL fluid samples were spiked with a quantified positive clinical sample across the range of the assay (3x-300x LoD). These samples were then tested by both the SARS-CoV-2 Molecular Detection Assay and the FDA EUA RT-PCR assay in a blinded fashion and compared to the expected results. The results of the SARS-CoV-2 Molecular Detection Assay showed 100% concordance with the comparator FDA EUA RT-PCR assay and the expected results.
Table 7: Clinical Performance of the SARS-CoV-2 Molecular Detection Assay with Upper Respiratory Swab Samples (NP and Throat swabs)

<table>
<thead>
<tr>
<th>SARS-CoV-2 MDA</th>
<th>Expected results (as well as FDA EUA RT-PCR Assay)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pos</td>
</tr>
<tr>
<td>SARS-CoV-2 MDA</td>
<td>Pos</td>
</tr>
<tr>
<td></td>
<td>Neg</td>
</tr>
</tbody>
</table>

- Positive Percent Agreement: 100% (95% CI: 92.87% - 100%)
- Negative Percent Agreement: 100% (95% CI: 88.65% - 100%)

\(^a\) These samples consisted of 40 spiked NP swabs (20 spiked at 1x LoD; 20 spiked at 2x LoD) and 10 throat swabs spiked at 3x-300x LoD.

\(^b\) These samples consisted of 15 non-spiked NP swabs and 15 non-spiked throat swabs.

Table 8: Clinical Performance of the SARS-CoV-2 Molecular Detection Assay with Lower Respiratory Samples (Sputum and BAL Fluid)

<table>
<thead>
<tr>
<th>SARS-CoV-2 MDA</th>
<th>Expected results (as well as FDA EUA RT-PCR Assay)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pos</td>
</tr>
<tr>
<td>SARS-CoV-2 MDA</td>
<td>Pos</td>
</tr>
<tr>
<td></td>
<td>Neg</td>
</tr>
</tbody>
</table>

- Positive Percent Agreement: 100% (95% CI: 92.87% - 100%)
- Negative Percent Agreement: 100% (95% CI: 88.65% - 100%)

\(^a\) These samples consisted of 40 spiked sputum samples (20 spiked at 1x LoD; 20 spiked at 2x LoD) and 10 BAL fluid samples spiked at 3x-300x LoD.

\(^b\) These samples consisted of 15 non-spiked sputum and 15 non-spiked BAL samples.

The clinical performance of the SARS-CoV-2 Molecular Detection Assay was also evaluated by testing real patient specimens. 45 clinical NP samples were tested by the SARS-CoV-2 Molecular Detection Assay and an FDA EUA SARS-CoV-2 RT-PCR assay (Table 9). Among these 45 samples, 15 were determined to be positive for SARS-CoV-2 by an FDA EUA RT-PCR assay at the Minnesota Department of Health (n=7), the Wisconsin Department of Health (n=1) and at Mayo Clinic (n=7). All results were concordant and fulfills the requirement for confirmatory testing of at least 5 positive and 5 negative specimens.

Table 9: Comparison of the SARS-CoV-2 Molecular Detection Assay to an FDA EUA SARS-CoV-2 RT-PCR Assay Using Clinical Samples (n=45)

<table>
<thead>
<tr>
<th>FDA EUA SARS-CoV-2 RT-PCR assay</th>
<th>Pos</th>
<th>Neg</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2 MDA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pos</td>
<td>15</td>
<td>0</td>
</tr>
<tr>
<td>Neg</td>
<td>0</td>
<td>30</td>
</tr>
</tbody>
</table>

- Positive Percent Agreement: 100% (95% CI: 79.62% - 100%)
- Negative Percent Agreement: 100% (95% CI: 88.65% - 100%)
Additionally, test results of 21,149 clinical samples (21,037 upper respiratory and 112 lower respiratory samples) were analyzed for two-targets (FDA authorized assay) and single-target (modified assay) versions of SARS-CoV-2 Molecular Detection Assay using easyMag/eMAG extraction systems. The comparison data are shown in Table 10 and Table 11 below.

**Table 10: Comparison of Two-targets and Single-target Versions of the SARS-CoV-2 Molecular Detection Assay Using Clinical Upper Respiratory Samples (n=21,037*)**

<table>
<thead>
<tr>
<th>FDA EUA</th>
<th>SARS-CoV-2 MDA (Two-targets)</th>
<th>Pos</th>
<th>Indeterminate</th>
<th>Neg</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2 MDA (Single-target)</td>
<td>Pos</td>
<td>484</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Indeterminate</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Neg</td>
<td>0</td>
<td>0</td>
<td>20,551</td>
</tr>
<tr>
<td>Positive Percent Agreement</td>
<td>484/484 = 100% (95% CI: 99.2% - 100%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative Percent Agreement</td>
<td>20,551/20,551 = 100% (95% CI: 99.9% - 100%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indeterminate Rate</td>
<td>2/21,037 = 0.01%</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*NP swabs (n=19,411), NP/OP swabs (n=1,607), OP swabs (n=17), nasal swabs (n=2)

**Table 11: Comparison of Two-targets and Single-target Versions of the SARS-CoV-2 Molecular Detection Assay Using Clinical Lower Respiratory Samples (n=112*)**

<table>
<thead>
<tr>
<th>FDA EUA</th>
<th>SARS-CoV-2 MDA (Two-targets)</th>
<th>Pos</th>
<th>Indeterminate</th>
<th>Neg</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2 MDA (Single-target)</td>
<td>Pos</td>
<td>8</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Indeterminate</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Neg</td>
<td>0</td>
<td>0</td>
<td>104</td>
</tr>
<tr>
<td>Positive Percent Agreement</td>
<td>8/8 = 100% (95% CI: 67.6% - 100%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative Percent Agreement</td>
<td>104/104 = 100% (95% CI: 96.4% - 100%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indeterminate Rate</td>
<td>0/112 = 0%</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*BAL/bronchial washings (n=55), sputum (n=37), tracheal secretions/aspirates (n=20)